Go Pro
→ Has Dylan Jovine lost his mind? (From Behind the Markets) (Ad)tc pixel Free OCSAW Stock Alerts

Oculis (OCSAW) Competitors

Oculis logo
$3.00 -0.14 (-4.46%)
As of 09/23/2026 12:21 PM Eastern
Compare

OCSAW vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Oculis N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals' average media sentiment score of 0.00 equaled Oculis'average media sentiment score.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
Oculis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Oculis on 1 of the 1 factors compared between the two stocks.

How does Oculis compare to Biofrontera?

Oculis (NASDAQ:OCSAW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Oculis' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
Oculis Neutral
Biofrontera Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

Summary

Biofrontera beats Oculis on 1 of the 1 factors compared between the two stocks.

How does Oculis compare to Cingulate?

Oculis (NASDAQ:OCSAW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

In the previous week, Oculis' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Oculis Neutral
Cingulate Neutral

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Cingulate N/A N/A N/A

Summary

Oculis and Cingulate tied by winning 0 of the 0 factors compared between the two stocks.

How does Oculis compare to Clever Leaves?

Oculis (NASDAQ:OCSAW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Oculis has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

In the previous week, Oculis' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Oculis Neutral
Clever Leaves Neutral

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Clever Leaves beats Oculis on 3 of the 3 factors compared between the two stocks.

How does Oculis compare to Comera Life Sciences?

Oculis (NASDAQ:OCSAW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Oculis' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Oculis Neutral
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Summary

Comera Life Sciences beats Oculis on 1 of the 1 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCSAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCSAW vs. The Competition

Export
MetricOculisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.61B$7.32B$13.29B
Dividend YieldN/A2.63%2.52%12.57%
P/E RatioN/A792.28274.0625.69
Price / SalesN/A860.49637.8178.88
Price / CashN/A88.6477.8052.76
Price / BookN/A10.5910.406.32
Net IncomeN/A$2.81B$3.49B$359.73M
7 Day Performance-4.46%-0.14%-0.69%0.17%
1 Month Performance-41.06%-1.36%-3.18%-3.27%
1 Year Performance-55.02%2.85%15.13%5.58%

Oculis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCSAW
Oculis
N/A$3.00
-4.5%		N/A-53.8%$0.00N/AN/A32
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/A-25.4%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
flat		N/A-80.2%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
flat		N/A-85.3%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OCSAW) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel